Cymbalta

It is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength, Lupin says, adding it is the only generic manufacturer to offer all Duloxetine dosage strengths.

Lupin Q2 profit seen up 36% on better operating performance

Revenue may rise 23 percent to Rs 3,270 crore in the second quarter of current financial year 2014-15 compared to Rs 2,668 crore in the year-ago period driven by strong growth in US.

Aurobindo Q3 net profit up 355% to Rs 417cr

Aurobindo Pharma surpassed all street expectations in third quarter FY14 with highest ever profit numbers. A healthy and improved product mix and increase in sale of high margin products has pushed profitability higher for the company, reports CNBC TV18‘s Archana Shukla.

Early gains for generics in Cymbalta patent expiry: Sources

Cymbalta, which is used to treat depression and anxiety disorders, lost patent protection on December 12.

Lily's Cymbalta patent expiry, little cheer for generic cos

Latest patent expiration of Eli Lily‘s anti-depressant drug Cymbalta, which had annual US sales of USD 5.5 billion, has not materialised as anticipated by the Indian generic drug makers, reports CNBC TV18‘s Archana Shukla.

Drugmaker Eli Lilly to cut 1,000 US sales jobs: Source

Drugmaker Eli Lilly and Co plans to lay off about 1,000 domestic sales representatives, or 30 percent of its U.S. sales force, as it faces new generic competition for its top drugs, a person familiar with the matter said on Friday.

Wockhardt gets tentative USFDA nod for anti-depression drug

Pharma and bio-technology company Wockhardt has received tentative approval from the US Food and Drugs Administration (FDA) for marketing 20mg, 30mg and 60mg delayed release capsules of Duloxetine Hydrochloride, a drug used for treating depression.